Who owns NEWAMSTERDAM PHARMA CO NV?
- Ticker: NAMS
- CUSIP Number: n62509109
Tip: Access positions for across all investors
Analyze quarterly positions in Newamsterdam Pharma Co Nv with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Newamsterdam Pharma Co Nv stock
Who bought or sold NEWAMSTERDAM PHARMA CO NV this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Frazier Life Sciences Management | 12M | $289M | 1% | Mar 2024 |
|
| Fcpm Iii Services B.v. | 12M | $280M | 0% | Mar 2024 |
|
| Bain Capital Life Sciences Investors | 11M | $248M | 0% | Mar 2024 |
|
| Viking Global Investors | 8.0M | $190M | 0% | Mar 2024 |
|
| RA Capital Management | 7.9M | $186M | 0% | Mar 2024 |
|
| Medicxi Ventures Management | 2.9M | $68M | 0% | Mar 2024 |
|
| Adage Capital Partners GP | 1.8M | $43M | 52% | Mar 2024 |
|
| BVF | 1.5M | $36M | 0% | Mar 2024 |
|
| Cormorant Asset Management | 1.5M | $36M | 100% | Mar 2024 |
|
| Goldman Sachs Group | 1.3M | $30M | -7% | Mar 2024 |
|
| Millennium Management | 948k | $22M | -29% | Mar 2024 |
|
| GMT Capital Corp | 943k | $22M | -32% | Mar 2024 |
|
| Jennison Associates | 931k | $22M | 100% | Mar 2024 |
|
| Artal Group | 800k | $19M | 100% | Mar 2024 |
|
| Deerfield Management Company | 667k | $16M | 100% | Mar 2024 |
|
| Pictet Asset Management Holding SA | 650k | $15M | 100% | Mar 2024 |
|
| Henderson Group | 636k | $15M | 100% | Mar 2024 |
|
| Avidity Partners Management | 475k | $11M | 100% | Mar 2024 |
|
| Citadel Advisors | 454k | $11M | 2059% | Mar 2024 |
|
| Octagon Capital Advisors | 408k | $9.6M | 100% | Mar 2024 |
|
| Opaleye Management | 315k | $7.5M | 19% | Mar 2024 |
|
| Arrowpoint Asset Management | 297k | $7.0M | 100% | Mar 2024 |
|
| Axa | 249k | $5.9M | -12% | Mar 2024 |
|
| Ensign Peak Advisors | 246k | $5.8M | -44% | Mar 2024 |
|
| FMR | 244k | $5.8M | 100% | Mar 2024 |
|
| TimesSquare Capital Management | 229k | $5.4M | 100% | Mar 2024 |
|
| Parkman Healthcare Partners | 200k | $4.7M | -20% | Mar 2024 |
|
| Morgan Stanley | 178k | $4.2M | 10334% | Mar 2024 |
|
| Nantahala Capital Management | 175k | $4.1M | 100% | Mar 2024 |
|
| Perceptive Advisors | 175k | $4.1M | 100% | Mar 2024 |
|
| Monashee Investment Management | 170k | $4.0M | 100% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 122k | $2.9M | 82% | Mar 2024 |
|
| Marshall Wace | 115k | $2.7M | 240% | Mar 2024 |
|
| Moody Aldrich Partners | 111k | $2.6M | 100% | Mar 2024 |
|
| Baker Bros. Advisors | 97k | $2.3M | 100% | Mar 2024 |
|
| J. Goldman & Co | 79k | $1.9M | 100% | Mar 2024 |
|
| Artia Global Partners | 54k | $1.3M | 100% | Mar 2024 |
|
| Geode Capital Management | 52k | $1.2M | 25% | Mar 2024 |
|
| Two Sigma Investments | 52k | $1.2M | 100% | Mar 2024 |
|
| UBS Group | 48k | $1.1M | 5935% | Mar 2024 |
|
| Alyeska Investment Group | 36k | $843k | -88% | Mar 2024 |
|
| Lighthouse Investment Partners | 29k | $694k | 100% | Mar 2024 |
|
| Y-Intercept | 26k | $620k | 100% | Mar 2024 |
|
| Yarbrough Capital | 24k | $567k | 100% | Mar 2024 |
|
| Cubist Systematic Strategies | 23k | $544k | 100% | Mar 2024 |
|
| HealthInvest Partners AB | 22k | $530k | 100% | Mar 2024 |
|
| Sei Investments | 17k | $390k | 100% | Mar 2024 |
|
| M^T Bank Corporation | 16k | $372k | 100% | Mar 2024 |
|
| Cinctive Capital Management | 15k | $356k | 100% | Mar 2024 |
|
| Glenmede Trust Company | 13k | $300k | 100% | Mar 2024 |
|
| Venture Visionary Partners | 12k | $277k | 17% | Mar 2024 |
|
| BlackRock | 11k | $265k | -51% | Mar 2024 |
|
| Two Sigma Advisers | 9.1k | $215k | 100% | Mar 2024 |
|
| Envestnet Asset Management | 9.0k | $214k | 100% | Mar 2024 |
|
| Atlantic Trust | 7.6k | $163k | -41% | Mar 2024 |
|
| Wolverine Asset Management | 7.1k | $169k | -18% | Mar 2024 |
|
| Us Bancorp | 6.5k | $153k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 4.3k | $102k | 100% | Mar 2024 |
|
| Royal Bank of Canada | 3.5k | $82k | -68% | Mar 2024 |
|
| Bank of America Corporation | 2.0k | $47k | 100% | Mar 2024 |
|
| Canton Hathaway | 1.0k | $24k | 100% | Mar 2024 |
|
| Bradley & Co. Private Wealth Management | 729.00 | $17k | 100% | Mar 2024 |
|
| Signature | 647.00 | $15k | 100% | Mar 2024 |
|
| PSI Advisors | 500.00 | $12k | 100% | Mar 2024 |
|
| Wells Fargo & Company | 500.00 | $12k | 67% | Mar 2024 |
|
| Stone House Investment Management | 325.00 | $7.7k | 100% | Mar 2024 |
|
| Barclays | 94.00 | $2.0k | -82% | Mar 2024 |
|
| Principal Securities | 5.00 | $118.000000 | 100% | Mar 2024 |
|
| DuPont Capital Management Corporation | 1.00 | $24.000000 | 0% | Mar 2024 |
|
Who sold out of Newamsterdam Pharma Co Nv?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Cutler | Dec 2023 | 500.00 | $5.0k |
| Atticus Wealth Management | Dec 2023 | 100.00 | $1.1k |